Citigroup Inc Cassava Sciences Inc Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Cassava Sciences Inc stock. As of the latest transaction made, Citigroup Inc holds 42,259 shares of SAVA stock, worth $114,944. This represents 0.0% of its overall portfolio holdings.

Number of Shares

42,259

Previous 18,337 130.46%

Holding current value

$114,944

Previous $226,000 450.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$9.57 - $35.08 $228,933 - $839,183	23,922 Added 130.46%	42,259 $1.24 Million
Q2 2024 Aug 12, 2024	SELL	$12.35 - $26.11 $43,064 - $91,045	-3,487 Reduced 15.98%	18,337 $226,000
Q1 2024 May 10, 2024	BUY	$18.44 - $26.41 $17,757 - $25,432	963 Added 4.62%	21,824 $442,000
Q4 2023 Feb 09, 2024	BUY	$12.64 - $30.11 $88,391 - $210,559	6,993 Added 50.43%	20,861 $469,000
Q3 2023 Nov 09, 2023	SELL	$16.64 - $25.32 $158,296 - $240,869	-9,513 Reduced 40.69%	13,868 $230,000
Q2 2023 Aug 10, 2023	BUY	$21.59 - $27.88 $172,698 - $223,012	7,999 Added 52.0%	23,381 $573,000
Q1 2023 May 11, 2023	BUY	$23.46 - $36.44 $48,116 - $74,738	2,051 Added 15.39%	15,382 $371,000
Q4 2022 Feb 09, 2023	SELL	$27.82 - $44.16 $40,839 - $64,826	-1,468 Reduced 9.92%	13,331 $393,000
Q3 2022 Nov 10, 2022	SELL	$16.33 - $51.06 $73,272 - $229,106	-4,487 Reduced 23.27%	14,799 $619,000
Q2 2022 Aug 10, 2022	BUY	$17.22 - $38.47 $60,183 - $134,452	3,495 Added 22.13%	19,286 $543,000
Q1 2022 May 12, 2022	SELL	$32.6 - $53.05 $227,874 - $370,819	-6,990 Reduced 30.68%	15,791 $587,000
Q4 2021 Feb 10, 2022	SELL	$36.77 - $90.91 $592,732 - $1.47 Million	-16,120 Reduced 41.44%	22,781 $996,000
Q3 2021 Nov 10, 2021	BUY	$41.79 - $135.3 $1.63 Million - $5.26 Million	38,901 New	38,901 $2.42 Million

Others Institutions Holding SAVA

# of Institutions

203

Shares Held

13.9M

Call Options Held

2.98M

Put Options Held

6.57M

View Full List

About CASSAVA SCIENCES INC

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $109M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

More about SAVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account